What is AOD-9604 studied for in research?

AOD-9604 is studied as a modified hGH(176-191) fragment within lipolysis and adipose-metabolism research models. It is for research use only and is not approved for human use.

How is AOD-9604 different from HGH Fragment 176-191?

Briefly, AOD-9604 replaces the 176-191 fragment's N-terminal phenylalanine with tyrosine. See our HGH Fragment 176-191 vs AOD-9604 comparison for the full side-by-side treatment.

Is AOD-9604 doctoral chemist tested?

Yes. Each lot is independently assayed by HPLC for purity and by mass spectrometry to confirm the mass of the tyrosine-substituted fragment, and it ships with a lot-matched Certificate of Analysis reporting identity and purity of 99% or higher.

COMPOUND GUIDE 5 MIN READ

AOD-9604: Research Overview and Mechanism

AOD-9604 is a modified analog of the human growth hormone 176-191 fragment carrying a tyrosine substituted for its N-terminal phenylalanine, studied in laboratory and preclinical research within lipolysis and adipose-metabolism models. It retains the native disulfide bridge and is a frequently referenced GH-fragment tool compound. It is supplied as a lyophilized powder for research use only and is not approved for human use.

What AOD-9604 is

AOD-9604 is a synthetic analog of the C-terminal 176 to 191 fragment of human growth hormone, distinguished by a tyrosine substituted for the native phenylalanine at its N-terminus (position 176). Like the parent fragment, it retains the native cysteine-cysteine disulfide bridge, a structural feature studied in GH fragment structure-function research.

Because tyrosine differs from phenylalanine by only a single hydroxyl oxygen, this substitution changes the molecule's mass relative to the unmodified 176-191 fragment by just one oxygen atom, which is why the two are frequently referenced together as closely related tool compounds.

Pathways it is studied within

In preclinical research, AOD-9604 is investigated within lipolysis and adipose-metabolism models and within broader GH structure-activity questions. Unlike the unmodified parent fragment, AOD-9604 was advanced into human clinical trials for obesity by Metabolic Pharmaceuticals in the 2000s and progressed through Phase 2; in the larger Phase 2b trial the compound did not separate from placebo on its primary weight-loss endpoint, and that development program was subsequently discontinued. This clinical history is often cited when AOD-9604 is used as a reference GH-fragment tool compound, but it remains third-person research reporting about the molecule and is not human-use guidance.

Because it is structurally close to HGH Fragment 176-191, the two are often studied side by side to compare how the differing N-terminal residue affects the fragment's behavior in research models.

Handling and documentation

Pinnacle AOD-9604 is supplied as a 5mg lyophilized powder (CAS 221231-10-3) with a lot-matched Certificate of Analysis. Its C78H123N23O23S2 formula carries exactly one more oxygen than the unmodified 176-191 fragment, the signature of the tyrosine-for-phenylalanine substitution at its N-terminus, so its roughly 1815 g/mol mass reads slightly higher on the mass-spectrometry trace. Like the parent fragment it keeps a Cys7-Cys14 disulfide bridge, so it is stored at -20C away from light and reconstituted gently with bacteriostatic water.

All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.